Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063997 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT02063997 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 248 participants.
The verdict
NCT02063997, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
Interventions
- DRUG Placebo
- DRUG Colchicine 0.6 mg
- DRUG Arhalofenate 600 mg
- DRUG Allopurinol 300 mg
- DRUG Arhalofenate 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02063997
The ClinicalTrials.gov registry entry for NCT02063997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02063997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02063997 about?
NCT02063997 is a clinical study titled "Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients". The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
What is the current status of trial NCT02063997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2014-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02063997?
The interventions under investigation include: Placebo (DRUG), Colchicine 0.6 mg (DRUG), Arhalofenate 600 mg (DRUG), Allopurinol 300 mg (DRUG), Arhalofenate 800 mg (DRUG).
Who is sponsoring clinical trial NCT02063997?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.